cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Inozyme Pharma Inc
11 own
15 watching
Current Price
$2
$-0.8
(-28.75%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
238.98M
52-Week High
52-Week High
7.79500
52-Week Low
52-Week Low
1.97000
Average Volume
Average Volume
2.24M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization238.98M
icon52-Week High7.79500
icon52-Week Low1.97000
iconAverage Volume2.24M
iconDividend Yield--
iconP/E Ratio--
What does the Inozyme Pharma Inc do?
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company s lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More
How much money does Inozyme Pharma Inc make?
News & Events about Inozyme Pharma Inc.
Globe Newswire
1 year ago
BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options to new ...
Globe Newswire
1 year ago
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.(Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the companys senior vice...
Globe Newswire
1 year ago
- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and regulatory milestones remain on track with previous guidance - - Current cash, cash equivalents and short-term investments anticipated to ...
Globe Newswire
1 year ago
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the companys co-...
PR Newswire
1 year ago
Thinking about buying stock in Neximmune, Inozyme Pharma, Shopify, AMC Entertainment, or ContextLogic? Thinking about buying stock in Neximmune, Inozyme Pharma, Shopify, AMC Entertainment, or ContextLogic? PR Newswire NEW YORK, Feb. 16, 2023 NEW YORK, Feb. 16, 2023 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Inozyme Pharma Inc share price today?
plus_minus_icon
Can Indians buy Inozyme Pharma Inc shares?
plus_minus_icon
How can I buy Inozyme Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Inozyme Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Inozyme Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Inozyme Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Inozyme Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Inozyme Pharma Inc?
plus_minus_icon
What percentage is Inozyme Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Inozyme Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2
$-0.8
(-28.75%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
GENERATION BIO CO
GENERATION BIO CO
$0.93
$0.02 (1.76 %)
ADC Therapeutics SA
ADC Therapeutics SA
$1.88
$-0.04 (-2.08 %)
Design Therapeautics, Inc.
Design Therapeautics, Inc.
$4.52
$-0.55 (-10.94 %)
Nkarta Inc
Nkarta Inc
$2.35
$-0.04 (-1.67 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
GENERATION BIO CO
GENERATION BIO CO
$0.93
$0.02 (1.76 %)
ADC Therapeutics SA
ADC Therapeutics SA
$1.88
$-0.04 (-2.08 %)
Design Therapeautics, Inc.
Design Therapeautics, Inc.
$4.52
$-0.55 (-10.94 %)
Nkarta Inc
Nkarta Inc
$2.35
$-0.04 (-1.67 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00